MYRIAD GENETICS INC

MYGNNasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$824.5M

▼ 1.6% YoY

Net Income

-$365.9M

▼ 187.4% YoY

EPS

$-3.95

▼ 180.1% YoY

Cash

$149.6M

▲ 46.1% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.